skip to Main Content

Our story

Personalized wound healing

Diabetic foot ulcers have a debilitating impact on patients. Despite numerous treatment options, about 60% of all patients experience a wound that does not heal.46 If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound.47 For about 20% of patients, treatment ends in amputation within one year.48

At Reapplix, we have established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Using just a small sample of the patient’s blood – nothing else – the 3C Patch® System separates, coagulates and compacts the blood components into a solid patch. The result is a single 3C Patch® comprising a concentration of proteins, active cells and growth factors.

Each 3C Patch® takes about 20 minutes to produce and is applied directly to the wound at point-of-care. One of few evidence-based wound treatments, the 3C Patch® is clinically proven to significantly accelerate wound healing of hard-to-heal diabetic foot ulcers.1 The outcome is a cost-effective, personalized wound treatment that draws on each patient’s unique ability to help their own healing process.

Every wound is personal.

Please visit our corporate website

Every 20 seconds somewhere in the world someone loses a leg due to the complications of diabetes. At this moment, millions of people with diabetes suffer from poorly healing foot ulcers. These people can be helped when a multidisciplinary foot team shares common goals and follows evidence-based care.”

International Working Group on the Diabetic Foot45

Niels Erik Holm, Reapplix’s co-founder also invented the NovoLet pen, which has helped millions of diabetic patients all over the world since its introduction in the 1980s. Photo: Scanpix

Back To Top